Key takeaways
- Prescription pancreatic enzyme replacement therapy, or PERT, has an established place in care for diagnosed exocrine pancreatic insufficiency
- That medical role does not establish that an over-the-counter pancreatin product improves ordinary bloating or digestion in people without the condition
- Enzyme activity, release characteristics and the complete formulation matter; capsule weight alone cannot establish equivalence
- Major efficacy studies and some expert guidance have commercial connections that must remain visible
- Do not stop prescribed PERT, replace it with a supplement, or diagnose pancreatic insufficiency from a response to enzyme capsules
Direct answer: Prescription pancreatic enzyme replacement is used for diagnosed exocrine pancreatic insufficiency. That clinical role does not establish benefit from a generic OTC pancreatin product for ordinary bloating or IBS. The cited IBS pilot had an inconclusive primary comparison; the Crohn’s nutrition study was open and had unequal attrition. Company-supported absorption and symptom studies remain separate from this article’s independent-outcome screen. Funding uncertainty does not justify stopping prescribed treatment. [1], [3], [5].
Confidence is high in the recognized clinical role of prescribed PERT. Evidence for broad routine OTC digestive claims remains insufficient in the reports reviewed here. These are editorial judgments, not a new formal GRADE assessment, a complete trial census or a conflict-free brand comparison.
Table of contents
- Evidence summary
- What pancreatin is
- Forms and grades
- How it works
- Hype versus evidence
- Benefits by claim
- What works and what does not
- Risks and side effects
- Interactions and evidence gaps
- Who should avoid self-treatment
- Dosage and how it is studied
- Animal and laboratory evidence
- Independent funding tracing
- Frequently asked questions
- Sources and funding notes
Evidence summary
| Claim | Evidence | Source | Funding or conflict | Strength |
|---|---|---|---|---|
| Prescribed PERT is used for diagnosed pancreatic insufficiency | Current public clinical information and regulated drug indication | NIDDK and prescription label [1, 2] | Guidance and label facts; not a new independent efficacy trial | Established clinical role |
| A generic OTC pancreatin product treats ordinary bloating | No qualifying independent, product-relevant benefit evidence located | Review scope below | Cannot borrow prescription trials or blend results | Insufficient |
| Pancrelipase treats post-meal IBS-D | 49 randomized; primary treatment preference 30 versus 19, p=0.078; only 39 completed | Money et al [3] | Axcan supplied medicine and funded analysis/editing; additional author commercial ties | Excluded from independent verdict; exploratory symptom analyses |
| One formulation or dose is clearly best for everyone with cystic fibrosis | 14 short comparative trials, 641 participants; low or very low evidence for most comparisons | Cochrane review [4] | Review NIHR support; 8 company-supported trials, 3 funding unknown | No universal formulation or dose superiority established |
| PERT helps diarrhea during exclusive enteral nutrition in Crohn's disease | Open 16-week comparison; 43 per randomized arm, 38 versus 28 in per-protocol analysis | Kang et al [5] | Public/institutional grants; commercial test acknowledgement and product terms unresolved | Exploratory setting; unequal attrition and reporting inconsistencies |
| PERT cures pancreatic inflammation, cancer or every cause of malabsorption | No basis for these substitutions in the audited evidence | Scope appraisal | Treating an enzyme deficit is a different target | Not established |
What pancreatin is
Pancreatin is a preparation of pancreatic enzymes. Related prescription preparations are commonly described as pancrelipase; names, strength and formulation vary across markets. They include lipase, proteases and amylase, which act on different components of food. The referenced U.S. Creon preparation derives its enzymes from porcine pancreatic glands. [2]
This article covers that pancreatic-enzyme family. It does not treat isolated lipase, fungal proteases, pepsin or every multi-enzyme supplement as interchangeable ingredients.
Exocrine pancreatic insufficiency, or EPI, means inadequate pancreatic enzyme delivery or activity for digestion. Its clinical assessment is different from noticing fullness after a meal. NIDDK describes evaluation using medical history, examination and tests, including fecal elastase measured in a solid or semisolid stool sample. [6]
Forms and grades
| Form | Distinction that matters | Evidence boundary |
|---|---|---|
| Enteric-coated prescription capsules or pellets | Designed for a particular release profile and activity specification | Follow the prescribed product; release, enzyme activity and handling are product-specific [2], FDA label |
| Non-enteric-coated prescription preparation | Different administration and acid-management considerations | AGA advises acid suppression for non-enteric-coated preparations; instructions remain product-specific [10], original AGA report |
| OTC pancreatin powder, tablet or capsule | Activity, source and accompanying ingredients may differ | The ingredient name alone does not establish equivalence to PERT |
| Pancreatin plus other enzymes, acids or herbs | More than one potentially active ingredient | A blend outcome cannot identify pancreatin's independent contribution |
A pharmaceutical indication is a regulatory fact, not proof that every product sharing part of the name has the same evidence. Conversely, finding a sponsor in a drug trial does not transform a regulated medicine into an interchangeable supplement.
How it works
The pancreas normally supplies digestive juices that help process carbohydrate, fat and protein in the small intestine. NIDDK digestive-system overview explains this physiology. [7] Replacement is intended to compensate for inadequate enzyme function in an identified clinical setting.
The practical chain includes active enzyme, an appropriate formulation, contact with the food, and the intended site of action. More enzyme on a label does not automatically mean better symptom relief. A useful trial must characterize all of these features and measure an outcome relevant to its population.
Hype versus evidence
A familiar marketing leap starts with a true statement, “pancreatic enzymes digest food,” and ends with an untested conclusion, “therefore extra enzymes improve everyone's digestion.” A second leap takes evidence in diagnosed insufficiency and applies it to unexplained bloating. Neither establishes a consumer-product benefit.
The 2012 Abbott-funded trial randomized 62 adults with chronic pancreatitis and pancreatic insufficiency in India to pancreatin minimicrospheres or placebo for one week. The adjusted difference in change in fat absorption was 14.4 percentage points (95% CI 10.3–18.5). Stool consistency, flatulence and abdominal pain did not show a between-group advantage, and weight did not change. Adverse events occurred in 12/34 enzyme recipients and 7/28 placebo recipients; none was serious during this brief phase. Absorption improvement should not become a claim of universal symptom relief or long-term safety. [8].
The 2026 Othman study was an uncontrolled prospective study in adults with chronic pancreatitis and pancreatic insufficiency. Of 48 enrolled patients, 43 entered safety analysis and 42 the full analysis set; only 32 and 29 contributed the one- and three-month complete-case efficacy analyses. Questionnaire scores improved from baseline, but this cannot isolate a treatment effect. Stool and nutritional findings were limited, with no clear weight or grip-strength improvement. Three patients had eight serious events judged unrelated to the medicine; the study did not report an absence of serious events. [9].
Benefits by claim
Diagnosed exocrine pancreatic insufficiency
Established clinical role; independent product-comparison grade not assigned. NIDDK identifies prescribed PERT as treatment for EPI. [1] That clinical-care statement is kept separate from the outcome screen in this article. We are not presenting a pooled manufacturer-funded effect estimate as independent evidence, and we are not recommending that a patient abandon an established prescription because the research market has conflicts.
A 2017 chronic-pancreatitis/EPI meta-analysis included 17 randomized trials: 511 enrolled, 477 analyzed, with 14 trials in quantitative synthesis. Seven heterogeneous comparisons favored PERT for fat absorption; most blinded trials lasted days to at most two months. The article’s standardized/weighted effect terminology is inconsistent, so its reported 1.67 should not be read as a 1.67-percentage-point absorption gain. Nitrogen absorption versus placebo was not statistically significant in the two-trial comparison. Limited pain and adverse-event analyses do not prove broad symptom relief or long-term safety. Public/academic support and Abbott/Mylan consultant relationships were disclosed; this is not an independent pooled estimate. [16], original meta-analysis.
Cystic fibrosis and formulation choice
The 2020 Cochrane review included 14 trials and 641 participants: 12 crossover trials and two parallel trials. Thirteen lasted four weeks and one seven weeks; the search was current to November 2019. Most comparisons had low or very low certainty, with little basis for long-term nutritional or universal dose/formulation conclusions. Eight trials had company funding/support and three had unclear funding. The remaining three were rated as having no other funding-related bias; that is not a complete financial clearance. [4], review summary.
No eligible placebo comparison met this review’s minimum four-week duration and other selection rules. That does not mean no placebo-controlled pancreatic-enzyme study exists. The review received NIHR infrastructure support and its authors declared no interests; these declarations do not make its underlying trials independent. Uncertainty about the best formulation also does not remove the clinical need to treat diagnosed insufficiency. [4].
Post-meal IBS-D, bloating and general digestion
The Money pilot enrolled 69 people and randomized 49 with food-triggered IBS-D; 39 completed the crossover study. Its intention-to-treat preference comparison was 30 choosing enzyme versus 19 placebo, p=0.078. The authors identified a strong first-treatment/order effect. Positive symptom findings chiefly concerned the selected 25 completers who preferred the enzyme, rather than proving benefit across all randomized patients. [3].
The study tested Viokase before trigger meals, not a generic retail supplement. Preference-selected symptom analyses and an open follow-up cannot reliably establish broad IBS efficacy or diagnose EPI. Axcan supplied the medicine free and paid for statistical analysis and initial editing, while declaring no planning or conduct role. Local grants and private donations were also reported. Coauthor Talley disclosed relationships with Novartis, Takeda, GlaxoSmithKline, Dynogen and Tioga; amounts and complete financial terms were not reported. [3].
Diarrhea during specialized Crohn's nutrition therapy
Kang’s 2025 single-center study randomized 43 adults with nutrition-related diarrhea to PERT and 43 to no PERT during 16 weeks of biologic treatment and exclusive enteral nutrition. The 61 patients without nutrition-related diarrhea were not a third randomized arm. The comparison was open and used 38 versus 28 patients in per-protocol analysis. Diarrhea and symptom-based disease-activity results were favorable, but endoscopic and inflammatory outcomes did not demonstrate a clear corresponding advantage. Unequal attrition and inconsistent screened/withdrawn counts, percentages and stool reporting limit interpretation. [5].
Six Chinese government or institutional programs were listed as support, and the authors declared no conflicts. The acknowledgement says the fecal-elastase test was “approved by” Heruie; its precise commercial arrangement is unclear. Payment or donation terms for the test, enzymes and nutrition products were not established. Public grants and a no-conflict declaration therefore leave financial independence unresolved. This protocol is not evidence for routine self-treatment of Crohn’s disease or ordinary diarrhea. [5], NSFC constitution.
Pancreatic pain, inflammation and cancer claims
No substitution supported. Replacing digestive enzymes is a distinct treatment target. This article does not establish that pancreatin suppresses pancreatic inflammation, treats cancer or replaces disease-specific care. When EPI accompanies another disease, enzyme management and treatment of the underlying disease are separate clinical decisions.
What works and what does not
| Claim | Verdict | Notes |
|---|---|---|
| Prescribed PERT has a recognized role in EPI care | Yes, as clinical context | A diagnosis-specific medical treatment [1] |
| An OTC product is equivalent because it lists pancreatin | Not established | Source, activity, release and formulation matter |
| Feeling better on enzymes diagnoses EPI | Not reliable | Assessment needs the clinical picture and appropriate testing [6, 10] |
| More enzyme is always better | Unsupported and potentially unsafe | Dose escalation requires clinical oversight |
| Sponsored evidence must be false | Incorrect | A funding exclusion is an editorial rule, not a finding of fraud |
| A nonprofit review makes all included trials independent | Incorrect | Underlying funding still has to be checked |
Risks and side effects
| Aspect | Finding | Source |
|---|---|---|
| High doses, especially in children with cystic fibrosis | The cited label warns of fibrosing colonopathy, especially prolonged high doses in children with cystic fibrosis; reported pediatric strictures were associated with doses above 6,000 lipase units/kg/meal | Creon label [2] |
| Damaged coating or enzyme retained in the mouth | Oral irritation can occur | Creon label [2] |
| Gout, renal impairment or raised uric acid | Porcine enzymes contain purines; high doses may raise uric acid. The label advises considering monitoring in gout, renal impairment or existing hyperuricemia | Creon label [2] |
| Porcine protein sensitivity | Severe allergic reactions are reported. Discuss known porcine-protein sensitivity with the prescribing team; the cited label lists no formal contraindications | Creon label and ASHP patient information [2, 11] |
| Persistent or worsening abdominal symptoms | May need reassessment rather than another supplement or a larger dose | Clinical context [6, 12] |
Safety note: Do not experiment with replacing a prescription, crushing a formulation or escalating its dose. Administration differs by product. Severe or worsening abdominal pain, vomiting with systemic illness, jaundice or shortness of breath warrant urgent assessment. [12]
Interactions and evidence gaps
| Substance or condition | Mechanism or concern | Severity or status | Source |
|---|---|---|---|
| Acarbose | Its labeling specifically names pancreatin and amylase among carbohydrate-splitting preparations that may reduce its effect | The acarbose label says these preparations should not be taken concomitantly; arrange prescriber/pharmacist review | Heritage/Avet manufacturer label [13] |
| Acid-suppressing treatment | Some prescribed formulations are used with acid suppression; others have protective coatings | Product-specific clinical decision; do not add acid or stop a PPI to “activate enzymes” | Expert guidance, with disclosed ties [10] |
| Other enzyme supplements | Combined activity may be hard to interpret | Avoid assuming doses can simply be added or substituted | Formulation and dose uncertainty |
| Medicines requiring close nutritional or metabolic control | Changes in digestive treatment can complicate care | Review the full regimen rather than an isolated ingredient | Clinical precaution, not a quantified interaction estimate |
The February 2024 Creon label expects no CYP- or transporter-mediated interactions because its enzymes are not relevant substrates. That narrow mechanism statement is not a complete interaction clearance: acarbose labeling separately warns about carbohydrate-splitting enzymes. These are manufacturer-origin label statements, even when hosted by a government service, rather than independently replicated interaction trials. FDA label, [13].
Who should avoid self-treatment
People with diagnosed or suspected pancreatic disease, unexplained weight loss, persistent greasy stools, recurrent diarrhea or significant nutritional problems need evaluation rather than a general enzyme experiment. EPI symptoms overlap with other conditions. [6, 14]
Tell the prescribing team about porcine sensitivity, prior bowel narrowing, gout or kidney impairment. Pregnancy, breastfeeding and pediatric use need product-specific clinical assessment. The cited label reports little systemic enzyme absorption and no identified pregnancy risk in published case reports, but limited data do not establish universal safety. Medically indicated replacement should not be stopped without advice. FDA label, [11].
Dosage and how it is studied
There is no generic pancreatin supplement dose established by this review for ordinary bloating or digestion. Prescription dosing and research exposures below are not instructions for self-treatment.
| Use case | Dose framework or research exposure | Duration | Notes |
|---|---|---|---|
| Prescribed pancreatic enzyme replacement | Activity expressed in lipase units and adjusted by the clinical team | Depends on the underlying condition | Dose by lipase activity with meals/snacks; adjust clinically and do not automatically substitute brands [2], FDA label |
| Chronic-pancreatitis research | 80,000 Ph. Eur. lipase units with meals and 40,000 with snacks in the studied protocol | One-week blinded phase in the 2012 trial | 62 randomized adults with diagnosed insufficiency; a research exposure, not a self-treatment regimen [8] |
| General OTC use without established EPI | No qualifying independently established dose located | Not established | A serving suggestion does not prove benefit |
Meal timing and handling instructions belong to the prescribed formulation. The referenced label says not to crush or chew Creon; its opening/mixing instructions specify acidic soft food and differ for infants. The same milligram amount or similar enzyme name does not establish interchangeability. These February 2024 instructions are not a survey of every current product label. [2], FDA label, [11].
Animal and laboratory evidence
Enzyme activity in a laboratory can confirm that a preparation breaks down a substrate. It does not establish relief of unexplained bloating, treatment of IBS, long-term nutritional benefit or comparative safety. Animal microbiome studies and mechanistic claims were not used to establish human outcomes in this article.
Independent funding tracing
Research funding at a glance
16 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.

The ingredient family has no single owner. Prescription manufacturers, ingredient suppliers, supplement sellers and retailers have different commercial roles. Their financial interests should be identified without inventing a common controlling party.
AbbVie’s 2025 Form 10-K reports U.S. Creon net revenue of $1.512 billion and identifies its principal executive offices in North Chicago, Illinois, USA. These are issuer-reported commercial facts under securities-reporting obligations, not effectiveness measures or proof of a manufacturing country. Every subsidiary, supply-chain owner and product’s country of manufacture was not audited. [15].
AbbVie’s 2026 proxy statement reports beneficial holdings of 10.02% for Vanguard and 8.09% for BlackRock, with percentages calculated against shares outstanding on 6 March 2026. The underlying ownership reports were older: June 2025 and December 2023 respectively. These are published snapshots, not verified live holdings, and do not establish control over a study. The proxy is a primary corporate filing, USA, Tier 4/C for ownership facts, with securities accountability and stale underlying dates as its important limitation.
The documented research relationships are more useful than speculation about motives:
- Abbott funded and supplied the 2012 Indian trial, managed randomization, and paid for DATAMAP statistical analyses and Envision medical writing; authors also disclosed Pfizer, Solvay, Abbott and Dr. Reddy’s relationships. [8].
- Axcan supplied free Viokase and funded analysis/initial editing; local grants and private donations were also listed. The IBS pilot disclosed additional pharmaceutical relationships for Talley. [3].
- AbbVie funded the 2026 study and participated in design, research, collection, analysis, interpretation, writing, review and publication approval. It paid for Citrus medical writing and PPD/Thermo Fisher analysis; company employees and other author commercial ties were disclosed. [9].
- UK NIHR infrastructure support → Cochrane review; this does not erase commercial support in included trials [4]
- Chinese public and institutional grants → Kang study; commercial-product procurement and the test acknowledgment remain unresolved [5]
Commercial support is a reason for transparent exclusion under this article's standard, not proof of false findings. Public grant support also deserves scrutiny rather than an automatic clean bill of independence.
The 2023 AGA report was society-commissioned expert advice, without a systematic review or formal GRADE ratings. Whitcomb reported AbbVie, Nestlé and Regeneron consultancy and Ariel cofounder/board/CSO/equity interests; Buchner reported Olympus consultancy; Forsmark reported AbbVie research and Nestlé consultancy. Dedicated report funding was not located. The original report supports clinical-practice context, rather than a conflict-free primary experiment. [10], original AGA report.
Source credibility scorecard
Tier concerns documented financial proximity; A–D concerns suitability for the limited source role. Both are editorial judgments, not formal clinical GRADE or a certificate of complete independence. A government host does not change who wrote a label or funded a trial. Where support, supplier terms or author finances are unreported, uncertainty remains explicit.
| Source | Funding or revenue and country | Tier and grade | Accuracy incentive and remaining gap |
|---|---|---|---|
| [1] NIDDK EPI treatment | U.S. federal public-health institute | Provisional 1; A for clinical context | Clinical public guidance; complete page-specific and underlying-study financial chains unreported |
| [2] Creon prescribing information | AbbVie-authored regulated labeling; USA | 4; C for identity and warnings | Legal labeling obligations; commercial origin and brand specificity |
| [3] Money pilot | Axcan free medicine and analysis/editing finance; local grants/private donors and Talley commercial ties | 4 for support; D for independent-outcome eligibility | Original methods/disclosures transparent; inconclusive ITT preference, order effects and selected symptom subgroup |
| [4] Cochrane CF review | UK NIHR infrastructure; UK-based review organization, authors in India and Costa Rica | 1 provisional for review declaration; B for comparative audit | Search November 2019; short trials and low/very low comparisons, with company-supported and unknown underlying finances |
| [5] Kang 2025 | Chinese government, university and hospital grants; ambiguous company test acknowledgment | Unresolved financial tier; C for causal benefit claim | Open study, unequal attrition and denominator/reporting inconsistencies; commercial supply terms unreported |
| [6] NIDDK EPI diagnosis | Federal public-health source; USA | Provisional 1; A for diagnostic context | Public diagnostic context; no reader diagnosis or full page-finance clearance |
| [7] NIDDK physiology | Federal public-health source; USA | Provisional 1; A for basic biology | Basic digestive physiology; not an OTC trial or complete page-finance check |
| [8] Thorat 2012 | Abbott finance/product/randomization/analysis/writing; additional author commercial ties; India trial | 4; D for independent-outcome eligibility | One-week fat absorption benefit; no clear stool-consistency/pain/flatulence difference and no long-term outcome inference |
| [9] Othman 2026 | AbbVie all-stage finance/role, employees and other author relationships; USA | 4; D for independent-outcome eligibility | Uncontrolled complete-case symptom changes; attrition, limited nutrition measures and unrelated serious events reported |
| [10] AGA 2023 expert review | Society-commissioned; authors report relevant commercial relationships; USA | 3 for author commercial proximity; B for attributed practice advice | Expert advice without systematic review/formal GRADE; dedicated report finance unlocated |
| [11] ASHP patient information on MedlinePlus | Nonprofit professional publisher; licensing, business and corporate-support activities; USA | 2; B for medication safety context | ASHP editorial separation policy is a self-disclosure; NIH hosting does not clear licensing/ad/business and author finance |
| [12] NIDDK pancreatitis warnings | Federal publication; acknowledges a specialist whose later AGA disclosures include industry ties; USA | 2 provisional; A for warning-sign context | Generic safety guidance; later disclosures do not prove a tie influenced the 2017 page |
| [13] Acarbose label | Heritage/Avet producer-origin regulated U.S. drug label | 4; C for stated interaction warning | Supports its explicit pancreatin/amylase warning; no clinical magnitude or exhaustive interaction audit |
| [14] NIDDK EPI symptoms | Federal public-health source; USA | Provisional 1; A for context | Public symptom information; overlap requires assessment, and page-specific finances are unreported |
| [15] AbbVie 2025 Form 10-K | Public issuer, drug sales; USA | 4; C for financial facts | Securities reporting and audit; financial incentives remain direct |
| [16] de la Iglesia-García meta-analysis | Hospital, Royal College of Surgeons and NIHR support; Abbott/Mylan consultancy/lecture/travel ties | 2/3; B for transparent review context | Short heterogeneous trials and inconsistent effect terminology; underlying trial finances/supplements not fully re-audited |
NIDDK’s federal budget page describes appropriations and allocation, not a specific article’s financial clearance. ASHP reports corporate business activities; its AHFS DI policy describes subscription support, volunteer expert review and editorial/business separation, which does not establish the identical revenue chain for every patient publication. Cochrane’s 2024 accounts disclose publisher licensing/royalty income and other institutional support; its legal notice supplies UK registration and London location. These primary self-disclosures do not independently clear every donor, editor or review. NSFC’s constitution permits donations alongside central-government funding and does not resolve the commercial acknowledgement in Kang’s trial. NIDDK budget, ASHP corporate activities, AHFS editorial policy, Cochrane accounts, Cochrane identity, NSFC constitution.
The evidence is concentrated in specialist disease populations and a small number of countries, including the USA, India and China. A corporate headquarters, trial location, source publisher and manufacturing country are separate attributes.
Regulatory status
The referenced Creon preparation has a U.S. EPI prescription indication. Dietary supplements follow a different pathway and generally are not FDA-approved for safety and effectiveness before sale. FDA describes annual appropriations and Congressionally authorized industry fees restricted to their programs; fees do not determine approval decisions. We use these institutional sources for the stated U.S. regulatory rules, not a clinical-benefit estimate, UAE classification or product quality certificate. [2], FDA label, FDA supplement framework, FDA finance.
Frequently asked questions
Is pancreatin the same thing as pepsin?
No. This article concerns pancreatic-enzyme preparations. Pepsin is a different enzyme associated with the stomach. Evidence and product instructions should not be transferred between them.
If I feel better with enzymes, does that prove pancreatic insufficiency?
No. The AGA expert report states that response to a therapeutic enzyme trial is unreliable for diagnosing EPI. Assessment needs the clinical setting and appropriate tests; a watery stool can dilute fecal elastase, and an indeterminate result needs clinical interpretation. The report’s author commercial ties and narrative methods are disclosed above. [10], original AGA report, [6].
Should someone already prescribed PERT stop because studies have sponsors?
No. This article's strict screening rule is not a clinical instruction to stop treatment. Discuss treatment questions, symptoms or access problems with the prescribing team.
Can a cheaper supplement substitute for my prescription?
Equivalence is not established by the ingredient name or capsule weight. Any change needs review of the actual product and treatment plan.
Does this article prove no one without EPI benefits?
No. It finds insufficient independently verified evidence for broad routine OTC claims, while identifying narrower research questions worth testing.
Sources and funding notes
- NIDDK treatment for EPI
- Creon full prescribing information, revised February 2024, retrieved via DailyMed; FDA-hosted label PDF
- Money et al, pancrelipase for post-meal IBS-D, 2011
- Somaraju and Solis-Moya, Cochrane review, 2020; publisher plain-language record
- Kang et al, Crohn's enteral-nutrition diarrhea trial, 2025
- NIDDK diagnosis of EPI
- NIDDK digestive physiology
- Thorat et al, pancreatin minimicrospheres trial, 2012
- Othman et al, prospective observational study, 2026
- AGA clinical practice update, 2023; legally hosted original report, including methods and author disclosures [10], original AGA report.
- ASHP pancrelipase patient information on MedlinePlus
- NIDDK pancreatitis warning symptoms
- Acarbose label PDF, including pancreatin interaction warning
- NIDDK EPI symptoms and causes
- AbbVie 2025 Form 10-K filed with the SEC
- de la Iglesia-García et al, 2017 primary meta-analysis; accessible full original in PMC [16], original meta-analysis.
Review limits: This is a structured narrative review of the cited accessible primary reports, financial declarations, product labels and clinical context, not a registered systematic review or prescribing guideline. The relevant main clinical and financial sections of the Money, Thorat, Cochrane, Kang, Othman, AGA and de la Iglesia-García reports were read, but all historical trial originals, supplements, unpublished data and individual lifetime finances were not audited. The ASHP corporate page was available only through indexed primary passages; the separate AHFS policy was read. Company-funded/supplied results remain outside the independent-outcome verdict, and unknown financial support remains unknown. No independent pooled treatment effect, universal brand ranking or latest-label census is claimed.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
